Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cigna Corp (CI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cigna Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Cigna Corp trades at $290.93 (market cap $75.82B). The key difference: Cigna Corp is far larger — about 16.9× ACADIA Pharmaceuticals Inc.'s market cap, and Cigna Corp pays a 2.18% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CI | |
|---|---|---|
Market Cap | $4.49B | $75.82B |
Sector | Health | Health |
52-Week High | $28.06 | $312.00 |
52-Week Low | $20.06 | $244.41 |
Enterprise Value | $3.69B | $98.92B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Cigna (CI) trades at $286.62, down 0.4% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 11.95 and consistent earnings beats, including Q1 2026 EPS of $7.79 versus $7.60 expected. Revenue grew to $273.85B in 2025, and the company is expanding into AI-driven healthcare services, as highlighted by recent news of Evernorth's Pharmacy Forward initiative (PRNewswire, 2026-07-01).
The outlook is positive given analyst consensus with a $338.91 price target and 73.68% buy ratings. Key risks include regulatory challenges, such as the Tennessee prescription access lawsuit (Reuters, 2026-06-12), and volatility in medical cost trends. The stock offers value with a dividend yield supported by a recent $1.56 payout, but investors should monitor execution in specialty pharmacy expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
